Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03335761 · ClinicalTrials.gov registry record · NA
InterStim® Amplitude Study
A NA study, sponsored by MedtronicNeuro.
- Completed
- Registry status
- NA
- Development phase
- 97
- Enrollment target
NCT03335761: Completed NA study, sponsored by MedtronicNeuro.
NCT03335761 is a NA study that has completed, run by MedtronicNeuro. The registered enrollment target is 97 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03335761, a NA study, has completed, sponsored by MedtronicNeuro.
- COMPLETED
- Registry status
- NA
- Development phase
- 97 participants
- Enrollment target
Study Summary
This feasibility study will explore the effects of three different InterStim amplitude settings on overactive bladder symptoms (OAB).
Primary Outcome
Symptoms related to OAB were evaluated using paper voiding diaries. Subjects were trained to complete the urinary voiding diaries for 3-days.
Interventions
- DEVICE InterStim Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2019-11-06 |
| Phase | NA |
What the finished NCT03335761 record still lists
NCT03335761 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which InterStim Therapy is the first listed.
NCT03335761 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03335761 about?
NCT03335761 is a clinical study titled "InterStim® Amplitude Study". This feasibility study will explore the effects of three different InterStim amplitude settings on overactive bladder symptoms (OAB).
What is the current status of trial NCT03335761?
This trial is currently completed. It is a NA study. The enrollment target is 97 participants. The study started on 2018-02-27. Estimated completion is 2019-11-06.
What interventions are being tested in trial NCT03335761?
The interventions under investigation include: InterStim Therapy (DEVICE).
Who is sponsoring clinical trial NCT03335761?
This trial is sponsored by MedtronicNeuro, which has 51 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03335761's enrollment target sits among peer trials
97 923rd of 2000 higher than 1,076 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI